The Effect of ADHD Stimulant Treatment on Weight Categories in Children and Adolescents
Shlomit Yaron1, Ronen Arbel2,3, Talish Razi2
1Schneider Children's Medical Center of Israel, P.O. Box 559, Petach Tikvah 4920235, Israel.
Abstract:
Objective: Pediatric overweight and obesity represent a growing public health concern with significant long-term implications. In children diagnosed with attention-deficit/hyperactivity disorder (ADHD), stimulant medications may alter appetite, potentially impacting body weight and growth patterns. However, real-world data on the effect of these treatments on body mass index (BMI) classification remains scarce. We aimed to evaluate the effect of ADHD stimulant therapy on transitions in the BMI categories among children. Study Design: We conducted a large-scale observational cohort study assessing longitudinal changes in BMI classification following the initiation of stimulant treatment, utilizing data from Clalit Health Services, Israel's largest healthcare provider. BMI was categorized into four groups: normal weight, overweight, obesity, and severe obesity. Subgroup analysis was performed by sex and age groups: <7 years; >7 <13 years and >13 <18 years. Results: At baseline, 26,930 children met the study inclusion criteria. 12,448 (46%) were classified as overweight or obese. Most children with normal weight at baseline maintained their BMI classification (90%). 48% of children with overweight, 42% with obesity, and 29% with severe obesity transitioned to a lower BMI category. 39% of children with underweight transitioned to normal weight. Similar patterns in BMI category transitions were observed between sexes. Transition to a lower BMI category was more prevalent in the younger age group. Conclusions: Stimulant therapy for ADHD is associated with significant shifts in BMI classification among pediatric patients. While many children, especially younger with higher baseline BMI, experienced improvements in weight status, a notable minority exhibited weight gain. These findings underscore the importance of routine BMI monitoring and weight management strategies during ADHD treatment.
More Related Videos
05:48The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients
Published on: June 12, 2020
13:09Using Brain Activation nir-HEG/Q-EEG and Execution Measures CPTs in a ADHD Assessment Protocol
Published on: April 1, 2018
Related Concept Videos
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
Adrenergic Agonists: Mixed-Action Agents
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Stimulants
Cocaine can be administered via snorting, injection, or smoking. It primarily functions by blocking the reuptake of dopamine, resulting in a euphoric high characterized by an intense sensation of happiness and...
Adrenergic Agonists: Therapeutic Uses
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
